Saturday 17 October 2026
Export GTBP’s income statement to Excel — free account
GT Biopharma, Inc.
GTBP Healthcare Biotechnology
In the quarter to June 2026, EPS grew 98.9% and free cash flow fell 41.3%, each against the same quarter a year earlier.
7.03
0.33
−4.48%
Follow GTBP
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
3.27 | 3.50 | 4.14 | 2.61 |
Net Debt/EBITDA |
0.78 | 1.23 | 3.17 | 1.12 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(0.90) | 0.54 | 0.73 | 0.93 | |
Interest Coverage |
— | — | (45.21) | (70.50) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(23.33) | (18.24) | (2.04) | (2.74) | |
Cash per Share |
16.63 | 31.32 | 7.44 | 3.25 | |
Shareholders Equity per Share |
19.04 | 26.24 | 6.26 | 2.30 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
19.04 | 26.24 | 6.26 | 2.30 | |
Free Cash Flow |
(3.68) | (4.02) | (2.47) | (4.26) | |
Working Capital |
3.00 | 5.79 | 7.58 | 3.57 | |
Net Current Asset Value |
3.00 | 5.79 | 7.58 | 3.57 | |
| Other line items | |||||
Quick Ratio |
1.98 | 2.98 | 3.73 | 2.28 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(23.33) | (18.24) | (2.04) | (2.74) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
1.69 | 2.30 | 1.32 | 1.20 | |
Average Assets |
5.54 | 6.17 | 6.33 | 6.46 | |
Average Common Equity |
2.55 | 2.06 | 3.30 | (11.15) |
Columns are period end dates